Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 3
2012 9
2013 8
2014 5
2015 8
2016 10
2017 13
2018 14
2019 6
2020 15
2021 17
2022 38
2023 36
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J. Mascarenhas J. Expert Rev Hematol. 2022 Aug;15(8):671-684. doi: 10.1080/17474086.2022.2112565. Epub 2022 Sep 1. Expert Rev Hematol. 2022. PMID: 35983661 Review.
AREAS COVERED: This review will outline the pacritinib drug profile and summarize key efficacy and safety data, focusing on the 200 mg twice daily dose from phase 2 and 3 studies that formed the basis for the recent US Food and Drug Administration approval of pacritinib …
AREAS COVERED: This review will outline the pacritinib drug profile and summarize key efficacy and safety data, focusing on the 200 m …
Pacritinib: First Approval.
Lamb YN. Lamb YN. Drugs. 2022 May;82(7):831-838. doi: 10.1007/s40265-022-01718-y. Drugs. 2022. PMID: 35567653 Review.
Pacritinib (VONJO) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of myelofibrosis and graft-versus-host disease. ...The accelerated approval was based on results from the randomized, active-controlled, phase I …
Pacritinib (VONJO) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of m …
Pacritinib.
[No authors listed] [No authors listed] 2022 Jul 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Jul 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 35877951 Free Books & Documents. Review.
No information is available on the use of pacritinib during breastfeeding. The manufacturer recommends that breastfeeding be withheld during therapy and for 2 weeks after the last dose. ...
No information is available on the use of pacritinib during breastfeeding. The manufacturer recommends that breastfeeding be withheld …
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT. ...Clinical improvement in hemoglobin and reduction in transfusion …
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pacriti …
Pacritinib for myelofibrosis in adults with thrombocytopenia.
Yang DH, Lu Q, Zhu Z, Huang G, Young K. Yang DH, et al. Drugs Today (Barc). 2022 Dec;58(12):577-589. doi: 10.1358/dot.2022.58.12.3474538. Drugs Today (Barc). 2022. PMID: 36651066 Review.
Usually, these patients have an increased disease burden, increased transfusion dependence, shorter overall survival, and limited treatment options. Pacritinib is a new oral kinase inhibitor specifically targeting Janus kinase 2 (JAK2), interleukin-1 receptor-associated ki …
Usually, these patients have an increased disease burden, increased transfusion dependence, shorter overall survival, and limited treatment …
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Mesa RA, et al. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. Lancet Haematol. 2017. PMID: 28336242 Free PMC article. Clinical Trial.
We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. ...At week 24, the primary endpoint of SVR of 35% or more was achieved by 42 (19%) patients in the pacritinib g …
We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of …
Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D, Mascarenhas J. Tremblay D, et al. Expert Rev Hematol. 2018 Sep;11(9):707-714. doi: 10.1080/17474086.2018.1500456. Epub 2018 Jul 19. Expert Rev Hematol. 2018. PMID: 30001163 Review.
Areas covered: This review will describe the preclinical rationale for JAK2/FLT3 inhibition, review the pharmacology of pacritinib, and detail available clinical data for pacritinib treatment of myelofibrosis. The circumstances surrounding the full clinical hold tem …
Areas covered: This review will describe the preclinical rationale for JAK2/FLT3 inhibition, review the pharmacology of pacritinib, a …
Pacritinib Citrate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Jun 23;79(13):1031-1034. doi: 10.1093/ajhp/zxac109. Am J Health Syst Pharm. 2022. PMID: 35527647 No abstract available.
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Oh ST, et al. Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151. Blood Adv. 2023. PMID: 37552106 Free PMC article.
The impact of pacritinib on transfusion independence (TI) has not been previously described, nor has the mechanism by which pacritinib improves anemia been elucidated. ...These data indicate that the anemia benefit of the JAK2/IRAK1 inhibitor pacritinib may b …
The impact of pacritinib on transfusion independence (TI) has not been previously described, nor has the mechanism by which pacrit …
Pacritinib.
[No authors listed] [No authors listed] 2023 Dec 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Dec 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 38471026 Free Books & Documents. Review.
Pacritinib is a small molecule Janus kinase inhibitor that is used in the treatment of intermediate or high risk, primary or secondary myelofibrosis. Pacritinib is associated with transient and usually mild elevations in serum aminotransferase during therapy but has …
Pacritinib is a small molecule Janus kinase inhibitor that is used in the treatment of intermediate or high risk, primary or secondar …
177 results

Searches related to "pacritinib"